deltatrials
Completed PHASE4 NCT00163202

Comparative Atorvastatin Pleiotropic Effects

A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis

Sponsor: Bio-Inova Life Sciences International

Conditions Coronary Arteriosclerosis Hypercholesterolemia
Interventions Atorvastatin Blood samples
Updated 7 times since 2017 Last updated: Feb 17, 2021 Started: Jun 30, 2002 Completion: Aug 31, 2005

Listed as NCT00163202, this PHASE4 trial focuses on Coronary Arteriosclerosis and Hypercholesterolemia and remains completed. Sponsored by Bio-Inova Life Sciences International, it has been updated 7 times since 2002, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bio-Inova Life Sciences International
  • MDS Pharma Services
  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Besançon, France, Bełchatów, Poland, Bratislava, Slovakia, Brest, France, Brno-Bohunice, Czechia, Bucharest, Romania, Calgary, Canada, Chambéry, France, Chicoutimi, Canada, Clamart, France and 49 more location s